FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
This article was originally published in Pharmaceutical Approvals Monthly
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.
You may also be interested in...
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.